Park Medi World Q1 FY27: Growth With a Clear Capacity Roadmap

Park Medi World Limited entered FY27 in expansion mode, but the first quarter also showed what it takes to keep execution steady while the asset base grows. For Q1 FY27, the company reported revenue of ₹4,757 million, up 19 percent year on year from ₹3,988 million. EBITDA came in at ₹1,261 million, up 20 percent year on year, with EBITDA margin at 26.5 percent. Net profit rose faster than operating profit, reaching ₹886 million, up 35 percent year on year. Net profit margin improved to 18.6 percent from 16.4 percent a year ago.

Management framed the quarter as one of consolidation and continued execution. The focus during Q1 FY27 was on ramping up newer facilities, especially Agra and Panchkula, while preparing the next wave of growth across Uttarakhand, NCR, and Punjab. That context matters because operating metrics show the classic trade-off that comes with rapid capacity addition: more beds and higher patient volumes, but a near-term dilution in occupancy as new units scale.

Operationally, bed capacity increased to 3,960 beds as of June 30, 2026, a 32 percent year-on-year rise. Occupancy, however, declined to 55.6 percent from 67.8 percent in Q1 FY26. At the same time, volumes were strong. OPD patients increased to 223,000 from 191,000, and IPD patients rose to 250,000 from 214,000, a 17 percent year-on-year increase. The story of the quarter is therefore not just growth, but the company’s ability to protect profitability while absorbing new capacity.

The quarter in numbers and what moved them

The income statement shows a business still posting growth while managing a changing cost structure. Revenue rose 3 percent sequentially versus Q4 FY26. EBITDA was marginally lower than Q4 FY26, and margin moved from 27.7 percent in Q4 FY26 to 26.5 percent in Q1 FY27. This compression aligns with the company’s stated ramp-up phase at newer assets.

Costs increased broadly in line with the scale-up. Employee costs grew 20 percent year on year to ₹924 million. Professional and consultancy fees rose 25 percent year on year to ₹756 million, and other expenses increased 21 percent year on year to ₹1,054 million. Despite these increases, EBITDA still grew 20 percent year on year, indicating that the company maintained operating leverage even as it expanded.

Below EBITDA, the picture improved sharply. Finance costs dropped to ₹98 million from ₹151 million in Q1 FY26, a 35 percent reduction, supporting profit expansion. Net profit grew 35 percent year on year to ₹886 million, and EPS increased to ₹2.05 from ₹1.70.

Scale-up is visible, and the portfolio is built for acuity

Park Medi World’s network scale has become central to the investment case. As of the presentation date, the company operated 17 hospitals with 4,290 beds, including 1,166 ICU beds. The company also highlighted 30 plus super-speciality and specialty services, along with a cluster-based approach that aims to benefit from proximity between hospitals.

The portfolio is built to handle higher-acuity care. The presentation listed major equipment across the network, including 19 MRI units, 17 cath labs, 17 CT scanners, and 125 dialysis stations. It also highlighted 90 plus operation theatres and a meaningful ICU footprint. This matters because management is also tracking the clinical mix. Super-speciality mix improved by 440 basis points year on year, moving from 57.3 percent in Q1 FY26 to 61.7 percent in Q1 FY27.

Revenue remains firmly IPD led, which is typical for hospital operators with strong surgical and critical care capabilities. In Q1 FY27, in-patient revenue contributed 94.4 percent of total revenue, while out-patient contributed 5.6 percent. OPD’s share increased from 4.3 percent in Q1 FY26, suggesting more traction in high-volume footfalls, diagnostics, and consult-led services, even while IPD remains the main driver.

Expansion and acquisitions are now the operating system

Management commentary set a clear tone: expansion is continuing, but integration and ramp-up remain the near-term priorities. During the quarter, the company was scaling newer assets at Agra and Panchkula. The Chairman also described several capacity moves that reshape the FY27 and FY28 bed trajectory.

A key development was the entry into Uttarakhand. On May 25, the company announced a definitive agreement to acquire 100 percent of The Medicity Hospital in Rudrapur, a 330-bed NABH-accredited multi super specialty facility, in an all-cash transaction valued at ₹177 crores. The presentation stated that the transaction was consummated on July 31 and the hospital was commissioned on August 2, 2026. Rudrapur had nil contribution in Q1 FY27.

Within the core NCR and Tricity clusters, capacity also continues to rise. Panchkula, a 350-bed multi super specialty hospital, was commissioned on April 10, 2026. Park also announced a 100-bed extension at its Palam Vihar facility in Gurugram, which will take consolidated Gurugram capacity to 750 beds, with the expanded facility operating as Park Platinum from November 2026.

On the inorganic side, the company announced the acquisition of a 150-bed hospital in Zirakpur for approximately ₹107 crores, all-cash, with consummation and launch expected in November 2026.

This expansion engine is supported by a long track record of acquisitions. The company has acquired and integrated 11 hospitals, adding 2,840 beds via acquisitions, with cumulative consideration paid of ₹9,991 million and an average consideration per bed of ₹3.5 million across all acquisitions till date. The acquisition list spans Faridabad, Karnal, Ambala, Behror, Palam Vihar, Sonipat, Jaipur, Mohali, Bhathinda, Agra, and Rudrapur.

Acquired assets are also central to the current financial mix. In Q1 FY27, acquisitions accounted for 65 percent of revenue, 69 percent of EBITDA, and 77 percent of profit after tax, while contributing 63 percent of beds as of June 30, 2026. This skew suggests that the company has been able to integrate and improve performance at acquired hospitals, though it also means future execution depends on continued integration discipline.

What the bed pipeline implies for utilization and margins

The most important forward-looking signal in the presentation is the quantified capacity roadmap. The company reported total bed capacity of 3,960 as of June 30, 2026, and indicated that capacity additions during calendar year 2026 will amount to 1,490 beds, a 46 percent increase over the calendar 2025 base of 3,250 beds. Management expects to exit FY27 at 4,740 beds and reach 5,740 beds by March 2028, adding a further 1,000 beds through FY28.

The expansion slide also framed the journey as roughly 59 percent bed growth by FY28, from 3,610 beds in FY26 to 5,740 beds in FY28P, with an additional 2,130 beds identified across greenfield, acquisition, and expansion. Specific projects and timelines included Zirakpur acquisition in November 2026, Narela acquisition of 200 beds in December 2026, Gorakhpur acquisition with 400 beds in April 2027, Mohali expansion of 150 beds by September 2027, Ambala expansion of 200 beds by October 2027, and a greenfield project in Rohtak of 250 beds in January 2028.

This pipeline helps explain the near-term occupancy softness. When capacity rises 32 percent year on year, occupancy can fall even if volumes are rising, because the denominator expands faster than the ramp-up. The key investor question becomes whether utilization and case mix can rise fast enough in FY27 and FY28 to protect margins, especially when the network is operating across 15 cities in 6 states.

Management also addressed funding, stating that the ramp-up and expansion are expected to be funded largely through internal accruals and IPO proceeds, without recourse to any material fresh debt. The presentation described the balance sheet position as negative net debt and highlighted liquidity, including ₹2,998 million in fixed deposits. It also noted equity optionality, citing promoter holding of about 82.9 percent and headroom for dilution up to the regulatory threshold of about 75 percent.

Industry backdrop: supply gap supports multi-year growth

The company positioned its growth within a supportive demand environment. The presentation cited a 10 to 12 percent CAGR for the healthcare delivery segment from FY24 to FY29P and an estimated requirement of about 3 million beds to bridge the demand-supply gap. It also highlighted government healthcare allocation of ₹1,06,530 crores in FY26 and a target of around 5 percent of GDP healthcare spend by 2030.

In North India, where Park has a strong footprint, the presentation emphasized bed density gaps versus the National Health Policy recommendation of 20 beds per 10,000 population. It cited India’s average bed density around 15 beds per 10,000 and a global average around 33 beds per 10,000, reinforcing the structural under-penetration argument.

Demand drivers listed included CGHS rate revision of about 10 to 15 percent, the scale of Ayushman Bharat with 40 plus crore cards and 9 plus crore hospitalizations, and the push for digital health through ABHA for faster claims and better access. It also cited rising health insurance coverage in India, from 288 million people in 2014 to 15 to 573 million in 2023 to 24, with a stated expectation of health insurance penetration increasing from 40 to 42 percent in FY24 to 45 to 50 percent in FY27.

Takeaways: execution is the differentiator in a high-growth phase

Q1 FY27 showed a company that is scaling quickly while keeping profitability intact. Revenue growth of 19 percent and net profit growth of 35 percent reflect steady demand and improved financial leverage, helped by lower finance costs. The softer occupancy rate is a logical outcome of rapid bed additions, and it puts the spotlight on ramp-up execution at newer hospitals.

The strategic message is consistent across the presentation. Park Medi World is building a cluster-led hospital network across North India and adjacent markets, using a mix of greenfield projects, brownfield expansions, and acquisitions. Acquired hospitals already contribute the majority of revenue, EBITDA, and profit, and the pipeline points to another step-up in capacity through FY28.

For investors, the near-term monitorables are clear. Utilisation trends need to improve as new capacity matures. Margin stability will depend on how quickly newer facilities reach steady-state occupancy, and how the super-speciality mix continues to shift toward higher-acuity services. If management delivers on integration and ramp-up while funding growth largely through internal accruals and IPO proceeds, the company’s stated bed roadmap to 5,740 beds by March 2028 becomes a tangible lever for sustained earnings scale.